BPC-157 Dosing in Hepatic Impairment: Evidence, Risks, and Clinical Guidance At a glance No FDA-approved formulation / BPC-157 is available only through 503A compounding pharmacies Zero published human RCTs evaluating BPC-157 in hepatic impairment populations Animal models show hepatoprotective effects against NSAID, alcohol, and toxin-induced liver damage Standard compounded dose range is 200-500 mcg/day subcutaneously or intramuscularly Suggested starting dose in hepatic impairment is 200-250 mcg/day subcutaneously Peptides are cleared primarily by proteolytic degradation, not hepatic CYP450 metabolism Liver enzyme monitoring (ALT, AST, bilirubin) recommended at baseline and every 2-4 weeks BPC-157 has shown cytoprotective effects on gastric and intestinal mucosa in over 20 animal studies The FDA has not established hepatic dosing adjustments for BPC-157 Cycle length in liver-compromised patients: 4-6 weeks with reassessment before continuation What Is BPC-157 and How Does It Work
Designed for Standard Vials - Holds 1 30ml and 12 3ml vials in a compact peptide storage case Secure & Organized Fit - Custom slots keep vials firmly in place, working reliably as a vial case for daily storage Fridge & Freezer Ready - Fits neatly as a vial holder for fridge and freezer Lightweight & Travel-Friendly - Compact and easy to carry, for home or on-the-go use Practical Design - Features a mesh pocket for small accessories, keeping everything organized and easy to access
Key Takeaways B12 and lipo shots are support tools, not standalone solutionsthey require a balanced diet and regular exercise to be effective, as the FDA has not approved them as weight loss treatments
Many of these customers migrated to other vendors, increasing scrutiny of supplier quality practices across the industry
Vitamin B12 shots are typically given intramuscularlymeaning the injection is delivered directly into a muscle, most often in the upper arm (deltoid), thigh, or buttock
&srotate=0)
